The Challenges Of Developing A Therapy For Pregnant Women With A Rare Condition RARECast podcast

Artwork

Health Industry Business Health Care Rare Disease RARECast Health and Well-Being

Innhold levert av RARECast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av RARECast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

RARECast « »
The Challenges of Developing a Therapy for Pregnant Women with A Rare Condition

5M ago 27:03

Del

MP3•Episoder hjem

Innhold levert av RARECast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av RARECast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Hemolytic disease of the fetus and newborn is a rare autoantibody condition for which there is no approved therapy. It causes the mother’s immune system to attack and breakdown the red blood cells in her fetus or newborn. It is one of more than 10 immunological and neurological indications for which Johnson & Johnson is developing its experimental monoclonal antibody nipocalimab. We spoke to Katie Abouzahr, vice president of the autoantibody portfolio and maternal fetal disease area leader for Johnson and Johnson, about hemolytic disease of the fetus and newborn, the challenges of developing a therapy for a rare condition in pregnant women, and why nipocalimab has the potential to be a pipeline in a product.

… continue reading

490 episoder

#Health Industry #Business #Health Care #Rare Disease #RARECast #Health and Well-Being

Artwork

The Challenges of Developing a Therapy for Pregnant Women with A Rare Condition

28 subscribers

published 5M ago

Del

MP3•Episoder hjem

Innhold levert av RARECast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av RARECast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Hemolytic disease of the fetus and newborn is a rare autoantibody condition for which there is no approved therapy. It causes the mother’s immune system to attack and breakdown the red blood cells in her fetus or newborn. It is one of more than 10 immunological and neurological indications for which Johnson & Johnson is developing its experimental monoclonal antibody nipocalimab. We spoke to Katie Abouzahr, vice president of the autoantibody portfolio and maternal fetal disease area leader for Johnson and Johnson, about hemolytic disease of the fetus and newborn, the challenges of developing a therapy for a rare condition in pregnant women, and why nipocalimab has the potential to be a pipeline in a product.

… continue reading

490 episoder

#Health Industry #Business #Health Care #Rare Disease #RARECast #Health and Well-Being

כל הפרקים

×

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

Lytt til 500+ tema